Homarylamine (), also known as 3,4-methylenedioxy-N-methylphenethylamine (MDMPEA) or as METHYL-H, is a chemical compound of the phenethylamine and methylenedioxyphenethylamine (MDxx) family. It is the N-methyl derivative of homopiperonylamine (methylenedioxyphenethylamine; MDPEA; H). The drug was patented by Merck & Co. in 1956 and studied as an antitussive (cough suppressant) in 1961. It is a schedule I drug in the United States as a positional isomer of 3,4-methylenedioxyamphetamine (MDA).
Homarylamine was briefly mentioned by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved). According to Shulgin, homarylamine has been reported to be active as an antitussive (cough suppressant) at a dose of 30mg. No central effects were described as this dose. Shulgin tried this dose and experienced a little tightness of facial muscles, but no mental effects whatsoever.
Reaction of homarylamine with formaldehyde gives hydrastinine.
A practical application of homarylamine is in the synthesis of .
Analogues of homarylamine include homopiperonylamine (MDPEA), lobivine (MDDMPEA), lophophine (MMDPEA), MDA, MDMA, hydrastine, and hydrastinine, among others.